CONSULTANCY AGREEMENTConsultancy Agreement • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • England
This Consultancy Agreement (the “Agreement”) is effective from 1 April 2007 and is made between PROTHERICS PLC (“Protherics” or the “Company”) whose registered office is the Heath Business and Technical Park, Runcorn, Cheshire WA7 4QX (registered in England and Wales under number 02459087) and “STUART MICHAEL WALLIS of Briarwood, Nightingales Lane, Chalfont St. Giles, Buckinghamshire HP8 4SR trading as “Stuart Wallis Associates” (the “Consultant”) and replaces the consultancy agreement dated 1 September 1998 made between Therapeutic Antibodies (UK) Limited and “Stuart M Wallis” trading as “Stuart Wallis Associates” (the “Consultant”).
AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATIONThe Agreement and Plan of Merger and Reorganization • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • Utah
THIS AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, dated as of January 3, 2007 (this “Amendment”) is by and among Protherics PLC, a public limited company incorporated under the laws of England and Wales (registered number 2459087) (“PTI”), MacroMed Acquisition Corp., a Utah corporation and a direct, wholly-owned subsidiary of PTI (“PTI Merger Sub”), and MacroMed, Inc., a Utah corporation (the “Company”).
ONCOGEL/GENEXOL RESTATED LICENSE AND SUPPLY AGREEMENT Dated: JUNE 20th , 2006License and Supply Agreement • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • Utah
This RESTATED LICENSE AND SUPPLY AGREEMENT (hereinafter the “Restated Agreement”) is made and entered into , 2006 (the “Restated Agreement Date”), intended to be effective retroactively to November 23, 2001, by and between SAMYANG GENEX CORPORATION (“Genex”), a Korean corporation, having its principal place of business at 263 Yeonji-dong, Chongno-gu, Seoul, Korea, and MACROMED, INC. (“MacroMed”), a Utah corporation, having its principal place of business at 9520 South State Street, Sandy, Utah 84070, U.S.A. This Restated Agreement amends, restates, and supersedes, in its entirety, that certain OncoGel/Genexol License and Supply Agreement dated November 23, 2001 (the “Original Agreement”).
LICENSE AGREEMENT AMONG PROTHERICS MEDICINES DEVELOPMENT LIMITED (“PROTHERICS”) AND GLENVEIGH PHARMACEUTICALS, LLC, GLENVEIGH RESEARCH, LLC C. DAVID ADAIR, M.D. CDA ROYALTY INVESTORS LLC and CDA LICENSING ADMINISTRATORS LLC (collectively, “GLENVEIGH”)...License Agreement • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • Tennessee
This License Agreement (this “Agreement”), executed as of December 7, 2006 (the “Execution Date”), is made by and among, on the one hand, Protherics Medicines Development Limited, a company incorporated in England and Wales under number 1939643, being a wholly owned subsidiary of Protherics plc, and whose registered office is at The Heath Business and Technical Park, Runcorn, Cheshire WA7 4QX, England (“Protherics”), and on the other hand, Glenveigh Pharmaceuticals, LLC, a Delaware limited liability company with its principal place of business at 2530 Meridian Parkway, Suite 300, Durham, NC 27713, Glenveigh Research, LLC, a Tennessee limited liability company with its principal place of business at 979 E. Third Street, Suite C-825, Chattanooga, TN 37403, C. David Adair, M.D., an individual physician with offices at 979 E. Third Street, Suite C-825, Chattanooga, TN 37403, CDA Royalty Investors, LLC, a Delaware limited liability company with its principal place of business at 1403 Foulk
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • Tennessee
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of this 8th day of June, 2007, by and between Protherics Inc, (the “Company”), and Saul Komisar (“Employee”).
ContractAgreement • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • London
* Portions of this exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the Commission.
APPOINTMENT AS NON-EXECUTIVE CHAIRMAN OF PROTHERICS PLCProtherics PLC • August 13th, 2007 • Pharmaceutical preparations
This letter confirms the main terms of your appointment to the above office and replaces your letter of appointment dated 1 September 1998 with effect from 1 April 2007.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • California
This Exclusive License Agreement (this “Agreement”) is made as of 15th day of December, 2004 (“Effective Date”) by and between MacroMed, Inc., a Utah corporation, having its principal offices at 9520 S. State, Street, Sandy, Utah 84070 (“MacroMed”) and Diatos SA, a French corporation, having its principal offices at 166 boulevard du Montparnasse, 75014 Paris, France (“Diatos”). MacroMed and Diatos shall be referred to herein, collectively, as the “Parties,” and may be referenced individually as a “Party.”
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION dated as of December 7, 2006 by and among PROTHERICS PLC, MACROMED ACQUISITION CORP. and MACROMED, INC.Agreement and Plan of Merger and Reorganization • August 13th, 2007 • Protherics PLC • Pharmaceutical preparations • Utah
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, dated as of December 7, 2006 (this “Agreement”) is by and among Protherics PLC, a public limited company incorporated under the laws of England and Wales (registered number 2459087) (“PTI”), MacroMed Acquisition Corp., a Utah corporation and a direct, wholly-owned Subsidiary of PTI (“PTI Merger Sub”), and MacroMed, Inc., a Utah corporation (the “Company”).
